Gene therapy for inborn errors of immunity: past progress, current status and future directions
Rare Disease and Orphan Drugs Journal · 14.10.2025 · 4 (4)
DOI: 10.20517/rdodj.2025.42 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rare Disease and Orphan Drugs Journal, online erschienen am 14.10.2025. Verfasst von Robert Torrance und 2 weiteren Autor:innen. Beteiligte Einrichtung: UCL Institute of Immunity and Transplantation, UCL, London NW3 2PP, United Kingdom. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Medical Research Council.
Abstract (Originalsprache)
Inborn errors of immunity (IEIs), also known as primary immunodeficiencies, are a group of rare inherited disorders that affect the immune system. They result in severe, opportunistic infections, severe autoimmune manifestations and a predisposition to malignancy. The only curative treatment for many years has been allogenic haematopoietic stem cell transplantation (alloHSCT). However, this requires the availability of a suitable donor and has risks of morbidity and mortality. Autologous gene therapy (GT) abrogates the immunological complications of alloHSCT and uses the patient’s own cells, removing the need for a donor. Preclinical proof-of-concept and clinical trials in humans have demonstrated that GT is safe and effective and can be used to correct a variety of IEIs. In this review, we outline the progress in developing GT for IEIs over the last four decades. We describe the gene editing technologies available to correct IEIs and their current applications. We also examine advances in GT development, the challenges to its application, and discuss future developments in the field, including emerging in vivo approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UCL Institute of Immunity and Transplantation, UCL, London NW3 2PP, United Kingdom.
- Department of Haematology, University College London Hospitals NHS Foundation Trust, London NW1 2PG, United Kingdom.
ORCID-Profile: Thomas A Fox
Förderung
- Wellcome Trust
- Medical Research Council
Zitieren
APA
Torrance, R., Orf, K., & Fox, T. A. (2025). Gene therapy for inborn errors of immunity: past progress, current status and future directions. Rare Disease and Orphan Drugs Journal, 4(4). https://doi.org/10.20517/rdodj.2025.42
Vancouver
Torrance R, Orf K, Fox TA. Gene therapy for inborn errors of immunity: past progress, current status and future directions. Rare Disease and Orphan Drugs Journal. 2025;4(4). doi:10.20517/rdodj.2025.42
BibTeX
@article{Torrance2025,
author = {Torrance, Robert and Orf, Kate and Fox, Thomas A},
title = {Gene therapy for inborn errors of immunity: past progress, current status and future directions},
journal = {Rare Disease and Orphan Drugs Journal},
year = {2025},
volume = {4},
number = {4},
doi = {10.20517/rdodj.2025.42}
}
EUVIMED